Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck’s LIPFENDRA (once-daily oral PCSK9 inhibitor) received FDA approval to reduce LDL-C in adults with hypercholesterolemia. The approval positions the drug as the first and only once-daily oral PCSK9 option in the U.S., supporting a constructive outlook for Merck’s cardiovascular franchise.

Analysis

Merck’s LIPFENDRA (once-daily oral PCSK9 inhibitor) received FDA approval to reduce LDL-C in adults with hypercholesterolemia. The approval positions the drug as the first and only once-daily oral PCSK9 option in the U.S., supporting a constructive outlook for Merck’s cardiovascular franchise.